A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a digital asset treasury (“DAT”) company that has adopted BNB, the native cryptocurrency of the Binance blockchain ecosystem as our primary reserve asset. By using proceeds from financings, as well as potential cashflow from our operations, we seek to strategically accumulate BNB and utilize the accumulated BNB as a productive treasury asset to produce yield via Binance native and other decentralized (DeFi) finance opportunities. In addition, via our LineaRx, Inc. subsidiary (“LineaRx”), we are commercializing proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets. Our nucleic acid production solutions enable cell-free manufacturing of deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”), which are essential components for a new generation of advanced biotherapeutics, such as gene therapies, adoptive cell therapies, messenger RNA therapeutics and DNA vaccines, as well as diagnostic applications.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.5M | 2.1M | 2.1M | 13M | - | - |
| Net Income | -71M | - | - | - | -8.4M | -14M |
| EPS | $283.69 | $-134.23 | $-1,024,815.00 | $-228,150.00 | $-13,950.00 | $-31,050.00 |
| Free Cash Flow | 0 | -13M | -14M | -6.3M | -9.5M | -16M |
| ROIC | -180.2% | - | - | - | -69.7% | -174.1% |
| Gross Margin | 31.2% | 39.3% | 46.1% | 41.4% | - | - |
| Debt/Equity | 0.00 | 0.08 | 0.08 | 0.25 | 0.72 | 0.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -32M | -16M | -14M | -11M | -14M | -13M |
| Operating Margin | -2111.4% | -750.9% | -646.7% | -81.9% | - | - |
| ROE | -374.6% | - | - | - | -69.7% | -169.8% |
| Shares Outstanding | 5M | 4M | 0M | 0M | 0M | 0M |
BNB PLUS CORP. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 42.3%.
BNB PLUS CORP. (BNBX) has a 5-year average return on invested capital (ROIC) of -121.9%. This is below average and may indicate limited pricing power.
BNB PLUS CORP. (BNBX) has a market capitalization of $3M. It is classified as a small-cap stock.
BNB PLUS CORP. (BNBX) does not currently pay a regular dividend.
BNB PLUS CORP. (BNBX) operates in the Services-Testing Laboratories industry, within the Industrials sector.
BNB PLUS CORP. (BNBX) reported annual revenue of $2 million in its most recent fiscal year, based on SEC EDGAR filings.
BNB PLUS CORP. (BNBX) generated $-13 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BNB PLUS CORP. (BNBX) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
BNB PLUS CORP. (BNBX) reported earnings per share (EPS) of $-134.23 in its most recent fiscal year.
BNB PLUS CORP. (BNBX) has a 5-year average gross margin of 42.3%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for BNB PLUS CORP. (BNBX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BNB PLUS CORP. (BNBX) has a book value per share of $0.53, based on its most recent annual SEC filing.